Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5679 | 2021 |
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification BD Cheson, RI Fisher, SF Barrington, F Cavalli, LH Schwartz, E Zucca, ... Journal of clinical oncology 32 (27), 3059-3067, 2014 | 5453 | 2014 |
Revised response criteria for malignant lymphoma BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ... Journal of clinical oncology 25 (5), 579-586, 2007 | 5428 | 2007 |
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma A Rosenwald, G Wright, WC Chan, JM Connors, E Campo, RI Fisher, ... New England Journal of Medicine 346 (25), 1937-1947, 2002 | 4816 | 2002 |
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas BD Cheson, SJ Horning, B Coiffier, MA Shipp, RI Fisher, JM Connors, ... Journal of clinical oncology 17 (4), 1244-1244, 1999 | 4341 | 1999 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma RI Fisher, ER Gaynor, S Dahlberg, MM Oken, TM Grogan, EM Mize, ... New England Journal of Medicine 328 (14), 1002-1006, 1993 | 3034 | 1993 |
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 MB Atkins, MT Lotze, JP Dutcher, RI Fisher, G Weiss, K Margolin, ... Journal of clinical oncology 17 (7), 2105-2105, 1999 | 2567 | 1999 |
A prognostic score for advanced Hodgkin's disease D Hasenclever, V Diehl, JO Armitage, D Assouline, M Björkholm, ... New England Journal of Medicine 339 (21), 1506-1514, 1998 | 2291 | 1998 |
Follicular lymphoma international prognostic index P Solal-Céligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ... Blood 104 (5), 1258-1265, 2004 | 2230 | 2004 |
Stromal gene signatures in large-B-cell lymphomas G Lenz, G Wright, SS Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, ... New England Journal of Medicine 359 (22), 2313-2323, 2008 | 2053 | 2008 |
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma RE Davis, VN Ngo, G Lenz, P Tolar, RM Young, PB Romesser, ... Nature 463 (7277), 88-92, 2010 | 1970 | 2010 |
Oncogenically active MYD88 mutations in human lymphoma VN Ngo, RM Young, R Schmitz, S Jhavar, W Xiao, KH Lim, ... Nature 470 (7332), 115-119, 2011 | 1805 | 2011 |
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1762 | 2020 |
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. G Fyfe, RI Fisher, SA Rosenberg, M Sznol, DR Parkinson, AC Louie Journal of clinical oncology 13 (3), 688-696, 1995 | 1729 | 1995 |
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group SF Barrington, NG Mikhaeel, L Kostakoglu, M Meignan, M Hutchings, ... Journal of clinical oncology 32 (27), 3048-3058, 2014 | 1727 | 2014 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma TM Habermann, EA Weller, VA Morrison, RD Gascoyne, PA Cassileth, ... Journal of clinical oncology 24 (19), 3121-3127, 2006 | 1700 | 2006 |
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells SS Dave, G Wright, B Tan, A Rosenwald, RD Gascoyne, WC Chan, ... New England Journal of Medicine 351 (21), 2159-2169, 2004 | 1674 | 2004 |
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1413 | 2021 |
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma A Rosenwald, G Wright, K Leroy, X Yu, P Gaulard, RD Gascoyne, ... Journal of Experimental Medicine 198 (6), 851-862, 2003 | 1367 | 2003 |
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma TP Miller, S Dahlberg, JR Cassady, DJ Adelstein, CM Spier, TM Grogan, ... New England Journal of Medicine 339 (1), 21-26, 1998 | 1357 | 1998 |